A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C.

Trial Profile

A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Lomibuvir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms ZENITH
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
    • 18 May 2012 Planned end date changed from 1 Jan 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov
    • 22 Apr 2012 Results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top